OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Development Research is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Research Progress of Endoplasmic Reticulum Targeting Metal Complexes in Cancer Therapy	123
Susceptibility of Leishmania to novel pentavalent organometallics: Investigating impact on DNA and membrane integrity in antimony(III)‐sensitive and ‐resistant strains	97
Safety study of topical naltrexone therapy for diabetic skin wounds is confirmed in Göttingen mini‐pigs	78
	72
A growth‐based assay using fluorescent protein emission to screen for S‐adenosylmethionine synthetase inhibitors	69
Trifolirhizin targets PTK6 to induce autophagy and exerts antitumor effects in nasopharyngeal carcinoma	50
Anti‐inflammatory effect and mechanism of catalpol in various inflammatory diseases	47
Design, synthesis, in vitro, and in vivo evaluation of novel phthalazinone‐based derivatives as promising acetylcholinesterase inhibitors for treatment of Alzheimer's disease	36
Knockdown of IGF2BP3 inhibits the tumorigenesis of gallbladder cancer and modifies tumor microenvironment	33
Therapeutic potential and research progress of diosgenin for lipid metabolism diseases	32
Novel matrinic acid derivatives bearing 2‐anilinothiazole structure for non‐small cell lung cancer treatment with improved Hsp90 targeting effect	30
Bioinformatics Exploration of the Therapeutic Potential of Lotus Seed Compounds in Multiple Sclerosis: A Network Analysis of c‐Jun Pathway	29
Advancements in Organoid‐Based Drug Discovery: Revolutionizing Precision Medicine and Pharmacology	29
Heteromerization, Biased Agonism, and Allosteric Modulation of G Protein‐Coupled Receptors in Addiction: Mechanistic Insights and Therapeutic Implications	29
Protective Effects of Herbacetin in Experimental Colitis: Targeting NF‐κB and NLRP3 Pathways	29
Secoisolariciresinol Diglucoside Alleviates LPS‐Induced Acute Lung Injury by Inhibiting the NF‐κB/NLRP3 Signaling Pathway	28
Synthesis and Biological Evaluation of π‐Conjugated Ir(III) Complexes: Cytotoxic Potential, DNA/HSA Binding, Thermodynamics, and Antioxidant Activity	28
Rational Discovery of BACE1‐Selective Inhibitors as Potential Therapeutics for Alzheimer's Disease	28
Recent Development in Celiac Disease: Pathophysiology, Animal Models and Treatments	28
Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells	26
T‐17, a novel cyclin‐dependent kinases/histone deacetylases dual inhibitor, induces cancer cells death through cell cycle arrest and apoptosis	26
Xanthatin induce DDP‐resistance lung cancer cells apoptosis through regulation of GLUT1 mediated ROS accumulation	25
Iridium(III) Complexes for Lung Cancer Therapy: Recent Advances and Case Studies in DNA Targeting, Antioxidant Activity and Cytotoxicity	25
Scopoletin Mitigates DSS‐Induced Ulcerative Colitis by Attenuating NF‐κB/MMP‐9 Mediated Inflammation and Activating the Nrf2 Pathway to Preserve Colonic Barrier Integrity	25
Dynorphin A Inhibits the Proliferation, Migration, Invasion, and Stemness of Triple Negative Breast Cancer Cells	25

Diaryl Diimidazopyrimidine Derivatives as Potent Inhibitors of Influenza A Virus: Synthesis, Evaluation and Docking Studies	25
Reduction‐Responsive RGD‐Docetaxel Conjugate: Synthesis, In Vitro Drug Release and In Vitro Antitumor Activity	25
Azole Amide Analogues as Antibacterial Agents Against Methicillin‐Resistant Staphylococcus aureus and Its Structure‐Activity Relationship Studies	25
Repurposing Nitroimidazoles: A New Frontier in Combatting Bacterial Virulence and Quorum Sensing via In Silico, In Vitro, and In Vivo Insights	25